Table 3.

Ongoing Phase III Clinical Trials on ALS Worldwide.

Clinical title	Study title	Agents	Locations
NCT04297683	Healey ALS platform trial-master protocol	Zilucoplan, Verdiperstat	United States
NCT05568615	Extension study following the studies MT-1186-A03 or A04 to evaluate the safety of oral edaravone in subjects with ALS	Edaravone MT-1186	Japan
NCT05151471	Efficacy and safety extension study of oral edaravone administered in subjects with ALS	Edaravone MT-1186	United States
NCT04768972	A study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of ION363 in amyotrophic lateral sclerosis participants with fused in sarcoma mutations	ION363	United States
NCT05193994	Triumeq in amyotrophic lateral sclerosis	Dolutegravir, Abacavir, Lamivudine	Australia
NCT04745299	Evaluation the efficacy and safety of mutiple lenzumestrocel treatment in patients with ALS	Riluzole, Lenzumestrocel	Korea
NCT05866926	A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with ALS	FAB122	Barcelona, Spain
NCT03127267	Efficacy and safety of masitinib vs. placebo in the treatment of ALS patients	Masitinib, Riluzole	United States
NCT05753852	Open Label extension of TUDCA-ALS study	Tauroursodeoxycholic	France
NCT04856982	A study of BIIB067 (Tofersen) initiated in clinically presymptomatic adults with a confirmed superoxide dismutase 1 mutation	Tofersen	United States
NCT04220190	RAPA-501 therapy for ALS	RAPA-501 autologous T cells	United States
NCT04057898	Evaluation of MN-166 (Ibudilast) for 12 months followed by an open-label extension for 6 months in patients with ALS	MN-166	United States
NCT04302870	Motor neurone disease-systematic multi-arm adaptive randomized trial	Trazodone, Memantine, Amantadine	United States
NCT05156320	Efficacy and safety of apitegromab in patients with later-onset spinal muscular atrophy treated with nusinersen or risdiplam	Apitegromab	United States